1-3 of 3
Morag Griffin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.

Clinical Trials & Observations
Ana Rita BM da Fonseca, Caio Cesar Justino, Vinicius Campos de Molla, Patricia Eiko Yamakawa, Iara Baldim Rabelo, Louise M Arnold, Richard J Kelly, Morag Griffin, Talha Munir, Anita Hill, Elvira D R P Velloso, Thales Dalessandro, Antonio Maria Risitano, Phillip Scheinberg, Austin G Kulasekararaj, Celso Arrais-Rodrigues
Journal: Blood Advances
Blood Adv bloodadvances.2024014159.
https://doi.org/10.1182/bloodadvances.2024014159
Published: 2024
Journal Articles

Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria

Clinical Trials & Observations
Régis Peffault de Latour, Morag Griffin, Richard J. Kelly, Jeff Szer, Carlos de Castro, Regina Horneff, Lisa Tan, Michael Yeh, Jens Panse
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2718–2725.
https://doi.org/10.1182/bloodadvances.2024012672
Published: 2024
Includes: Supplemental data
Journal Articles

Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH

Clinical Trials & Observations
Morag Griffin, Richard J Kelly, Jens Panse, Carlos de Castro, Jeff Szer, Regina Horneff, Lisa Tan, Michael Yeh, Régis Peffault de Latour
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1776–1786.
https://doi.org/10.1182/bloodadvances.2023011691
Published: 2024